Evidence map›Paper›PMID 32545832›Full record

ArticleToxins2020

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.

David Rupp, Greg Nicholson, David Canty, Joanne Wang, Catherine Rhéaume, Linh Le, Lance E Steward, Mark Washburn, Birgitte P Jacky, Ron S Broide and 3 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. [Expert consensus in Southwest China on the application of botulinum toxin type A in upper and mid-facial aesthetics].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. XeominToxins · 2023
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

David RuppAllergan, an AbbVie company, Irvine, CA 92612, USA.
Greg NicholsonAllergan, an AbbVie company, Irvine, CA 92612, USA.
David CantyAllergan, an AbbVie company, Irvine, CA 92612, USA.
Joanne WangAllergan, an AbbVie company, Irvine, CA 92612, USA.
Catherine RhéaumeAllergan, an AbbVie company, Irvine, CA 92612, USA.
Linh LeAllergan, an AbbVie company, Irvine, CA 92612, USA.
Lance E StewardAllergan, an AbbVie company, Irvine, CA 92612, USA.
Mark WashburnAllergan, an AbbVie company, Irvine, CA 92612, USA.
Birgitte P JackyAllergan, an AbbVie company, Irvine, CA 92612, USA.
Ron S BroideAllergan, an AbbVie company, Irvine, CA 92612, USA.
Wolfgang G Philipp-DormstonFaculty of Health, University Witten/Herdecke, 58455 Witten, Germany.
Mitchell F BrinAllergan, an AbbVie company, Irvine, CA 92612, USA.
Amy Brideau-AndersenAllergan, an AbbVie company, Irvine, CA 92612, USA.
AbbVie (United States) · USUniversity of California, Irvine · USWitten/Herdecke University · DE

Funding

Allergan N/A
6 · The paper itself

Abstract

Differences in botulinum neurotoxin manufacturing, formulation, and potency evaluation can impact dose and biological activity, which ultimately affect duration of action. The potency of different labeled vials of incobotulinumtoxinA (Xeomin

Indexed as

Action PotentialsAnimalsBiological AssayBotulinum Toxins, Type ACell Line, TumorDose-Response Relationship, DrugDrug LabelingFemaleHumansMiceMuscle, SkeletalNeuromuscular AgentsNeuronsParalysisRats, Sprague-DawleyBotulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agentsonabotulinum toxin ABOTOXcell-based potency assay (CBPA)compound muscle action potential (cMAP) electrophysiology assaydigit abduction score (DAS) assaydose conversioninterchangeabilitylight-chain activity high-performance liquid chromatograph (LCA-HPLC) assaypotencyXeomin

Identifiers

PMID32545832
PMCPMC7354455
OpenAlexW3034654938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.